News Headlines

  1. Asimov Launches Chrysalis Transposase, A Wholly-Owned Genome Integration Tool For Biotherapeutics Production 6/23/2026

    Asimov announces Chrysalis transposase, a proprietary genome integration tool engineered to deliver higher titers, greater expression stability, and faster cell recovery than conventional transposases.

  2. Orphan Therapeutics Accelerator Expands Its Network To Extend Development And Access Pathways For Ultra-Rare Disease Therapies 6/23/2026

    Orphan Therapeutics Accelerator (OTXL), a non-profit biotech focused on completing development and enabling commercial access to shelved rare disease treatments, today announced the expansion of its development network, Orphan ClinDevNet, through the addition of four strategic partners: OPIS, Uniphar, SK pharmteco, and TMC Pharma.

  3. CDMO Live & PharmaSource Acquired By Life Science Connect To Build The World's Leading Biopharma Outsourcing Platform 6/23/2026

    PharmaSource and CDMO Live, leading brands serving the biopharma outsourcing sector as part of Life Science Networks, announced today they have been acquired by Life Science Connect (LSC), a U.S.-based life sciences media business and portfolio company of Latticework Capital Management and Edgehill Management.

  4. VectorBuilder Partners With MaxCyte To Advance Clinical-Grade Cell Engineering 6/23/2026

    VectorBuilder, a global leader in gene delivery technologies and CDMO services, and MaxCyte, a leading, cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced a strategic partnership focused on co-developing a new gene delivery solution using VectorBuilder’s proprietary MiniVec plasmid system and MaxCyte’s world-class clinical electroporation platform for ex vivo cell engineering.

  5. Sartorius And LFB BIOMANUFACTURING Strengthen Collaboration 6/23/2026

    Sartorius and LFB BIOMANUFACTURING have announced an expansion of their collaboration with the aim of offering biopharmaceutical clients a comprehensive CLD to first batch of GMP drug substance service.

  6. FamiCord AG Wins ArThec As Another Customer In Its CDMO Business Area 6/23/2026

    FamiCord AG, Europe’s leading cell bank and the third largest worldwide, has entered into a framework agreement for collaboration with ArThec S.A. via its Polish subsidiary Polski Bank Komórek Macierzystych (PBKM). ArThec is a Polish company specializing in tissue engineering and regenerative medicine.

  7. Haisco Enters Into Exclusive License Agreement With Nuvectis For Two Drug Candidates In Oncology And Complement Indications 6/23/2026

    On June 23, 2026 (Beijing time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Nuvectis, a U.S. biotechnology company. Under the agreement, Haisco has granted Nuvectis the exclusive rights to develop, manufacture, and commercialize its independently developed innovative drug HSK42360 worldwide, excluding Greater China, as well as its independently developed innovative drug HSK39297 worldwide, excluding Greater China, India, and certain Southeast Asia territories.

  8. ProMed Pharma Announces Second Dedicated Manufacturing Suite Agreement At Niagara Lane Facility 6/23/2026

    ProMed Pharma, a leading contract development and manufacturing organization (CDMO) specializing in long-acting injectable and implantable drug delivery systems, today announced it has entered into an agreement with an undisclosed pharmaceutical partner to establish a second dedicated manufacturing suite within its Niagara Lane facility in Plymouth, Minnesota.

  9. Genetix Biotherapeutics And SPIMACO Announce Strategic Agreement To Commercialize And Manufacture LYFGENIA & ZYNTEGLO In Saudi Arabia And The Broader Middle East Region 6/23/2026

    Genetix Biotherapeutics Inc. and the Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) and its wholly owned subsidiary, SPIMACO Bio, today announced an exclusive collaboration and license agreement for the development, commercialization, and localized manufacturing of LYFGENIA and ZYNTEGLO in Saudi Arabia and across the broader Middle East.

  10. TrueLab Biopharmaceutical Announces License Agreement With Bionyra Pharma For Two Next-Generation Monoclonal And Bispecific Antibodies For Immune-Mediated Inflammatory Diseases Valued Up To $985M 6/22/2026

    TrueLab Biopharmaceutical, an immunology-driven innovator leveraging a proprietary, AI-powered R&D platform to develop transformative therapies for immune-mediated inflammatory diseases, today announced that it has entered into an exclusive license agreement with Bionyra Pharma, a newly launched clinical-stage biopharmaceutical company, for TL-001, an anti-TL1A monoclonal antibody, and TL-003, a TL1A × IL-23p19 bispecific antibody.